FDA wants another trial of GTx's prostate cancer drug
The FDA ordered GTx to conduct a second Phase III trial of toremifene citrate to prove the drug's efficacy in reducing fractures in prostate cancer patients. GTx CEO Mitchell Steiner said the agency should have informed the company that two such trials were needed, adding that there already is "sufficient information to satisfy the request."
American City Business Journals
| 11/2
This story published in FDLI SmartBrief on 11/03/2009
Get stories like these delivered daily for FREE:
|
FDLI SmartBrief
Designed specifically for professionals involved in the food and drug law community, FDLI SmartBrief is a FREE daily e-mail newsletter. It provides the latest need-to-know news and industry information that maximizes your time, giving you an edge over your competition. Learn more |
|